Literature DB >> 9682336

Towards an HIV-1 vaccine: lessons from studies in macaque models.

E G Hulskotte1, A M Geretti, A D Osterhaus.   

Abstract

The development of a safe and effective vaccine for the prevention of AIDS has thus far proven to be extremely difficult, at least in part due to complexities associated with HIV-1 and its pathogenesis. The recent description of individuals transiently infected with HIV-1, as well as persons who survived HIV-1 infection for more than 15 years, indicates the ability of the immune response of certain individuals to control HIV-1 infection. Moreover, vaccination-challenge experiments in macaques infected with simian immunodeficiency virus have shown that protection against infection or development of disease may be achieved in the absence of sterilizing immunity, suggesting that the goals for AIDS vaccine development may have to be redefined. In addition, evaluation of new lentivirus vaccine strategies may largely benefit from the use of the newly developed chimeric simian-human immunodeficiency viruses, allowing the testing of HIV-1 antigen based vaccines in macaques.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682336     DOI: 10.1016/s0264-410x(97)00292-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  The search for an HIV vaccine.

Authors:  Malegapuru William Makgoba; Nandipha Solomon; Timothy Johan Paul Tucker
Journal:  BMJ       Date:  2002-01-26

2.  Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Authors:  J J Kim; J S Yang; T C VanCott; D J Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  HIV: is a vaccine the answer?

Authors:  Sumit Chawla; Soumya Swaroop Sahoo; Rambilas Jain; Pardeep Khanna; Bharti Mehta; Inderjeet Singh
Journal:  Hum Vaccin Immunother       Date:  2013-09-04       Impact factor: 3.452

4.  Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef.

Authors:  E Khatissian; V Monceaux; M C Cumont; M P Kieny; A M Aubertin; B Hurtrel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses.

Authors:  David R M Graham; Megan J Mitsak; Steven T Elliott; Dawn Chen; Stephen A Whelan; Gerald W Hart; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2008-12       Impact factor: 3.984

6.  Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Authors:  J L Dzuris; J Sidney; H Horton; R Correa; D Carter; R W Chesnut; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Genetic variation at the mitochondrial large-subunit rRNA locus of Pneumocystis isolates from simian immunodeficiency virus-infected rhesus macaques.

Authors:  Karen A Norris; Hans Wildschutte; Jennifer Franko; Kathryn F Board
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

8.  Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.

Authors:  Yurie Nakaya; Takaaki Nakaya; Man-Seong Park; Jerome Cros; Jiro Imanishi; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  A comparative analysis of viral matrix proteins using disorder predictors.

Authors:  Gerard Kian-Meng Goh; A Keith Dunker; Vladimir N Uversky
Journal:  Virol J       Date:  2008-10-23       Impact factor: 4.099

Review 10.  The current state of animal models and genomic approaches towards identifying and validating molecular determinants of Mycobacterium tuberculosis infection and tuberculosis disease.

Authors:  Allison N Bucsan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Pathog Dis       Date:  2019-06-01       Impact factor: 3.166

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.